In the News

two strands of DNA

November 15, 2019 | BioSpace

Sarepta and StrideBio Announce Multi-target Strategic Collaboration to Advance Novel Gene Therapies

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, and StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, will collaborate to develop in vivo AAV-based therapies for up to eight central nervous system and neuromuscular targets.

Cartoon crystal structure of the TALEN gene editing technology. (Credit: Gersbach Lab)

November 4, 2019 | Duke Engineering News

The Evolution of Genetic Engineering

A Q&A with Charles Gersbach

October 14, 2019 | Duke GCB News

Weapon of Mass Congestion: Protection from Influenza Virus through Gene Control

DARPA recently awarded a grant to a Duke team for a multifaceted research effort aimed at temporarily regulating gene expression using RNA-based techniques that could help protect against pandemic flu by boosting lung resistance to the virus, attacking the virus directly, enhancing the immune system response and improving the effects of existing vaccines.

The Duke Center for Advanced Genomic Technologies aims to investigate and re-engineer the inner workings of cellular gene regulation machinery and networks

September 30, 2019 | Duke Engineering News

New Duke Center Takes Aim at the Dark Genome

Spanning Duke University and Duke Health, the Center for Advanced Genomic Technologies will use homegrown tools and techniques to discover potential therapies for human diseases from autism to cancer to schizophrenia


September 23, 2019 | Duke Engineering News

New CRISPR Class Expands Genetic Engineering Toolbox

In a recent study, Charles Gersbach and Adrian Oliver, a post-doctoral fellow in the Gersbach lab who led the project, describe how they successfully harnessed Class 1 CRISPR systems to turn target genes on and off and edit the epigenome in human cells for the first time.

Dewran Kocak

August 30, 2019

Caught Happily Between Labs

As a late-stage Ph.D. student, I find myself in a unique position to reflect on the culture here at Duke. It’s an exciting time to be a scientist, especially as my mentors join together with other research groups to launch the Center for Advanced Genomic Technologies (CAGT [...]

Kris Wood

April 23, 2019 | Illumina

Kris Wood's company Celldom accepted into Illumina Accelerator

Celldom, cofounded by Kris Wood, Zachary Forbes, and Bejamin Yellen, is a research tools company developing next generation, single-cell analysis technology to advance research and drug discovery and development by illuminating diversity in cell populations.

An artist’s representation of the CRISPR/Cas9 genetic sequence with the “hairpin” lock added to the left side of the system, which increases its precision by an average of 50-fold.

April 15, 2019 | Duke Engineering News

Engineering "Hairpins" Increases CRISPR Accuracy

An added piece of RNA could improve the precision of CRISPR 50-fold.

muscles of mice one year after gene-editing treatment

February 26, 2019 | NIH Director's Blog

More Progress Toward Gene Editing for Kids with Muscular Dystrophy

The Gersbach lab's latest work on gene editing for Duchenne Muscular Dystrophy was highlighted in the NIH Director's Blog.

two strands of DNA

February 18, 2019 | Duke Engineering News

Single Genetic Editing Treatment Provides Long-Term Benefits in Mice

Genetic edits and protein restoration in mouse models of Duchenne muscular dystrophy remain viable one year after single CRISPR treatment.


January 1, 2019 | The Scientist

Researchers Engineer Epigenome Editors to Study How Gene Expression Affects Disease

Using CRISPR and other tools, the Gersbach lab and other researchers are modifying DNA methylation, histone marks, and other modifiers of gene expression to understand how they affect health and disease.